The Special Meeting of Shareholders reconvenes on November 7, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will reconvene a Special Meeting of Shareholders (the “Special Meeting”) on November 7, 2025, at ...

The Special Meeting of Shareholders held on October 31, 2025 Shareholders vote on Equity Purchase Agreement with Sixth Borough Capital Fund RUTHERFORD, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced that it will hold a Special Meeting of Shareholders (the “Special Meeting”) on October 31, 2025, at 12 p.m. ET ...

Core Insights - Glucotrack, Inc. is participating in the Q3 Virtual Investor Summit on September 16-17, 2025, where management will present and hold one-on-one meetings with investors [1][2]. Company Overview - Glucotrack, Inc. (NASDAQ: GCTK) focuses on the design, development, and commercialization of innovative technologies for diabetes management [2]. - The company is developing a long-term implantable continuous blood glucose monitoring system aimed at improving the lives of people with diabetes [2]. Product Details - The Glucotrack Continuous Blood Glucose Monitoring (CBGM) system is designed to measure blood glucose levels continuously, featuring a sensor longevity of 3 years, no on-body wearable component, and minimal calibration requirements [3]. - The CBGM is currently classified as an Investigational Device and is limited to investigational use under U.S. law [3].